专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5280024A Medicinal use of 3',5'-di-tert.-butyl-4'-hydroxy flavones 失效
标题翻译： 3'，5'-二叔丁基-4'-羟基黄酮的药用
公开(公告)号：US5280024A
公开(公告)日：1994-01-18
申请号：US36814
申请日：1993-03-25
申请人： Yves Bolland , Guy Lewin , Jean-Paul Vilaine , Lenaers Albert , Catherine Thollon
发明人： Yves Bolland , Guy Lewin , Jean-Paul Vilaine , Lenaers Albert , Catherine Thollon
IPC分类号： A61K31/35 , A61K31/352 , A61K31/443 , A61K31/445 , A61K31/47 , A61K31/495 , A61K31/535 , A61P9/08 , A61P9/10 , C07D311/30 , C07D405/12
CPC分类号： C07D405/12 , C07D311/30
摘要： Compounds of the general formula (I): ##STR1## in which R represents: a hydrogen atom, ora radical --OR'in which R' is as defined in the description.
摘要翻译：通式（I）的化合物：其中R表示： - 一个氢原子，或 - 其中R'如说明书中所定义的-OR'。药剂

2. 发明授权

US5457103A 3',5'-di-tert.-butyl-4'-hydroxy flavones 失效
标题翻译： 3'，5'-二叔丁基-4'-羟基黄酮
公开(公告)号：US5457103A
公开(公告)日：1995-10-10
申请号：US108333
申请日：1993-08-18
申请人： Yves Rolland , Guy Lewin , Jean-Paul Vilaine , Albert Lenaers , Catherine Thollon
发明人： Yves Rolland , Guy Lewin , Jean-Paul Vilaine , Albert Lenaers , Catherine Thollon
IPC分类号： A61K31/35 , A61K31/352 , A61K31/443 , A61K31/445 , A61K31/47 , A61K31/495 , A61K31/535 , A61P9/08 , A61P9/10 , C07D311/30 , C07D405/12 , C07D413/02
CPC分类号： C07D405/12 , C07D311/30
摘要： Compounds of the general formula (I): ##STR1## in which R represents: a hydrogen atom, ora radical --OR'in which R' is as defined in the description.
摘要翻译：通式（I）的化合物：其中R表示：氢原子或其中R'如说明书中所定义的基团-OR'。

3. 发明授权

US06908922B2 Linear cyclic ureas 失效
标题翻译：线性循环脲
公开(公告)号：US06908922B2
公开(公告)日：2005-06-21
申请号：US10292358
申请日：2002-11-12
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D417/14 , A61K31/00 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/551 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P43/00 , C07D209/08 , C07D211/00 , C07D211/26 , C07D211/58 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/06 , C07D471/04 , C07D491/04 , C07D401/04 , C07D401/14
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions ins which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：V表示单键或亚烷基链，M表示单键或亚烷基链，A和E各自表示氮或CH，但两个基团A或E中的至少一个表示氮，W表示式（i），（ii）或（iii）的基团：含有该基团的药物，其可用于治疗已知内皮功能障碍的疾病或病理状况。

4. 发明授权

US06696469B2 Cyclobutenedione compounds 失效
标题翻译：环丁二酮化合物
公开(公告)号：US06696469B2
公开(公告)日：2004-02-24
申请号：US09976572
申请日：2001-10-12
申请人： Jean-Louis Peglion , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon , Christophe Poitevin
发明人： Jean-Louis Peglion , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon , Christophe Poitevin
IPC分类号： A61K31445
CPC分类号： C07D401/12 , C07D211/22 , C07D401/14 , C07D405/06 , C07D405/14 , C07D471/04 , C07D491/04
摘要： Compounds of formula (I): wherein: X represents a heterocycle bonded to the remainder of the molecule by a nitrogen atom of the heterocycle, or an —NR2R3 group wherein R2 represents hydrogen or alkyl, and R3 represents aryl, 1,3 dihydro-2H-benzimidazolyl-2-one or alkyl substituted by a heterocycle, n represents zero or 1, R1 represents hydrogen or alkyl, Ra represents a single bond or an alkylene chain, A represents nitrogen or CH, E represents nitrogen or CRe, wherein Re is as defined in the description, Rb represents a single bond or an alkylene chain as defined in the description, W represents aryl or heteroaryl, Their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful for treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：X表示通过杂环的氮原子与分子的其余部分键合的杂环，或其中R 2表示氢或烷基且R 3表示芳基的-NR 2 R 3基团， 2H-苯并咪唑基-2-酮或被杂环取代的烷基，n表示0或1，R1表示氢或烷基，Ra表示单键或亚烷基链，A表示氮或CH，E表示氮或CRe，其中Re 如说明书中所定义，R b表示如说明书中定义的单键或亚烷基链，W表示芳基或杂芳基，它们的光学异构体及其与药学上可接受的酸的加成盐，以及含有该酸的药物和含有它们的药物用于治疗已知内皮功能障碍的疾病或病理状况。

5. 发明授权

US06903103B2 Linear cyclic ureas 失效
标题翻译：线性循环脲
公开(公告)号：US06903103B2
公开(公告)日：2005-06-07
申请号：US10369860
申请日：2003-02-20
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D417/14 , A61K31/00 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/551 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P43/00 , C07D209/08 , C07D211/00 , C07D211/26 , C07D211/58 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/06 , C07D471/04 , C07D491/04 , C07D401/04 , C07D401/08 , C07D403/04
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：V表示单键或亚烷基链，M表示单键或亚烷基链，A和E各自表示氮或CH，但两个基团A或E中的至少一个表示氮，W表示式（i），（ii）或（iii）的基团：其中：X表示羰基，磺酰基或亚砜，G 1，G 2和 G 3如说明书中所定义，T表示稠合的苯基或稠合的吡啶基，R 1表示直链或支链的C 1（C 1 H 3）其中烷基部分是直链或烷基，其中烷基部分是直链或直链或支链烷基，分支的R 2a和R 2b相同或不同，如说明书中所定义，R 3表示芳基或杂芳基 - 如在说明书中所定义的A，每个基团可以任选被取代，Y代表描述中定义的芳氧基，杂芳氧基或杂芳基-B，每个 h基团可任选被取代，其异构体，其水合物，其溶剂合物及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。

6. 发明授权

US06566364B2 Linear or cyclic ureas 失效
标题翻译：线性或环状脲
公开(公告)号：US06566364B2
公开(公告)日：2003-05-20
申请号：US09751716
申请日：2000-12-29
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D40112
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：V表示单键或亚烷基链，M表示单键或亚烷基链，A和E各自表示氮或CH，但两个基团A或E中的至少一个表示氮，W表示式（i），（ii）或（iii）的基团：含有该基团的药物，其可用于治疗已知内皮功能障碍的疾病或病理状况。

7. 发明授权

US08076325B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them 有权
标题翻译： 1,2,4,5-四氢-3H-苯并氮杂化合物，其制备方法和含有它们的药物组合物
公开(公告)号：US08076325B2
公开(公告)日：2011-12-13
申请号：US12283110
申请日：2008-09-09
申请人： Jean-Louis Peglion , Bertrand Goument , Aimee Dessinges , Pascal Caignard , Jean-Paul Vilaine , Catherine Thollon , Nicole Villeneuve , Stefano Chimenti
发明人： Jean-Louis Peglion , Bertrand Goument , Aimee Dessinges , Pascal Caignard , Jean-Paul Vilaine , Catherine Thollon , Nicole Villeneuve , Stefano Chimenti
IPC分类号： A01N43/00 , A61K31/55 , C07D223/16
CPC分类号： C07D223/16
摘要： Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R2, R3, R4 and R5 each represent a hydrogen atom or a hydroxy, methyl, —OSO2R10, —OCOR10 or optionally substituted alkoxy group, or R2 and R3, or R3 and R4, or R4 and R5 together form a group —O—(CH2)q—O—, —O—CH═CH—O— or —O—CH═CH—, R6, R7, R8 and R9 each represent a hydrogen atom or an alkoxy group, or R6 and R7, or R7 and R8, or R8 and R9 together form a group —O—(CH2)q—O—, R10 represents a group selected from linear or branched C1-C6alkoxy, NR11R′11 and optionally substituted alkyl, R11 and R′11 each represent a hydrogen atom or an alkyl group, or R11 and R′11 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH2, m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.
摘要翻译：式（I）化合物：其中：R 1表示氢原子或选自环烷基，苄基和任选取代的烷基的基团，R 2，R 3，R 4和R 5各自表示氢原子或羟基，甲基，-OSO 2 R 10，-OCOR 10 或任选取代的烷氧基，或R 2和R 3，或R 3和R 4，或R 4和R 5一起形成基团-O-（CH 2）q -O-，-O-CH = CH-O-或-O-CH = CH-，R6，R7，R8和R9各自表示氢原子或烷氧基，或R6和R7，或R7和R8，或R8和R9一起形成-O-（CH 2）q -O-，R 10基团表示选自直链或支链C 1 -C 6烷氧基，NR 11 R 11和任选取代的烷基的基团，R 11和R 11各自表示氢原子或烷基，或者R 11和R 11与携带它们的氮原子一起形成任选取代的单环或双环含氮杂环，X表示O，NH或CH 2，m和p各自表示0或1，n和q各自表示1或2，以外消旋形式或i n是光学异构体的形式，以及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗各种病症。

8. 发明申请

US20090069296A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them 有权
标题翻译： 1,2,4,5-四氢-3H-苯并氮杂化合物，其制备方法和含有它们的药物组合物
公开(公告)号：US20090069296A1
公开(公告)日：2009-03-12
申请号：US12283110
申请日：2008-09-09
申请人： Jean-Louis Peglion , Bertrand Goument , Aimee Dessinges , Pascal Caignard , Jean-Paul Vilaine , Catherine Thollon , Nicole Villeneuve , Stefano Chimenti
发明人： Jean-Louis Peglion , Bertrand Goument , Aimee Dessinges , Pascal Caignard , Jean-Paul Vilaine , Catherine Thollon , Nicole Villeneuve , Stefano Chimenti
IPC分类号： C07D223/16 , A61K31/55
CPC分类号： C07D223/16
摘要： Compounds of formula (I): wherein: R1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R2, R3, R4 and R5 each represent a hydrogen atom or a hydroxy, methyl, —OSO2R10, —OCOR10 or optionally substituted alkoxy group, or R2 and R3, or R3 and R4, or R4 and R5 together form a group —O—(CH2)q—O—, —O—CH═CH—O— or —O—CH═CH—, R6, R7, R8 and R9 each represent a hydrogen atom or an alkoxy group, or R6 and R7, or R7 and R8, or R8 and R9 together form a group —O—(CH2)q—O—-, R10 represents a group selected from linear or branched C1-C6alkoxy, NR11R′11 and optionally substituted alkyl, R11 and R′11 each represent a hydrogen atom or an alkyl group, or R11 and R′1 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH2, m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers,and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.
摘要翻译：式（I）化合物：其中：R 1表示氢原子或选自环烷基，苄基和任选取代的烷基的基团，R 2，R 3，R 4和R 5各自表示氢原子或羟基，甲基，-OSO 2 R 10，-OCOR 10 或任选取代的烷氧基，或R 2和R 3，或R 3和R 4或R 4和R 5一起形成基团-O-（CH 2）q O - ， - O-CH-CH-O-或-O-CH-CH- ，R6，R7，R8和R9各自表示氢原子或烷氧基，或R6和R7，或R7和R8，或R8和R9一起形成-O-（CH2）qO-基，R10表示基团选自直链或支链C 1 -C 6烷氧基，NR 11 R 11和任选取代的烷基，R 11和R 11各自表示氢原子或烷基，或者R 11和R 11与携带它们的氮原子一起形成任选取代的，单环或双环，含氮杂环，X表示O，NH或CH 2，m和p各自表示0或1，n和q各自表示1或2，以外消旋形式或以旋光异构体的形式，其离子盐与药学上可接受的酸。含有该药物的药物可用于治疗各种病症。

9. 发明授权

US06323217B2 Piperidine-4 sulphonamide compounds 失效
标题翻译：哌啶-4-磺酰胺化合物
公开(公告)号：US06323217B2
公开(公告)日：2001-11-27
申请号：US09772569
申请日：2001-01-30
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
IPC分类号： A61K314725
CPC分类号： C07D401/12 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound of formula (I): wherein: R1 represents hydrogen or alkyl, R2a and R2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）化合物：其中：R 1表示氢或烷基，R 2a和R 2b表示选自氢，卤素，烷基，羟基，烷氧基，三卤代烷基，氰基，硝基，氨基，烷基氨基和二烷基氨基的基团，R 3表示氢或羟基，X表示氧或亚甲基，V表示任选不饱和且任选取代的亚烷基链，U表示键或亚烷基链，W表示选自芳基和杂芳基的基团，这些基团中的每一个可任选地被一个或多个更多相同或不同的基团，其异构体，其水合物，其溶剂合物及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。

10. 发明授权

US06780868B2 Linear cyclic ureas 失效
标题翻译：线性循环脲
公开(公告)号：US06780868B2
公开(公告)日：2004-08-24
申请号：US10371128
申请日：2003-02-20
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D40104
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compounds of formula (I): wherein: V represents a single bond or a linear or branched (C1-C6)alkylene chain, M represents a single bond or a linear or branched (C1-C6)alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i): X represents carbonyl, G1 represents a linear C3 alkylene chain optionally containing a double bond and/or being optionally substituted by a hydroxyl group, their isomers, their hydrates, their solvates, and additional salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）化合物：其中：V表示单键或直链或支链（C1-C6）亚烷基链，M表示单键或直链或支链（C1-C6）亚烷基链，A和E各自表示氮或CH，但两组A或E中的至少一个表示氮，W表示式（i）的基团：X表示羰基，G1表示任选含有双键的直链C 3亚烷基链和/或任选取代羟基，它们的异构体，它们的水合物，它们的溶剂化物，和其药学上可接受的酸的其它盐，以及含有该羟基的药物，可用于治疗已知内皮功能障碍的疾病或病理状况。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式